CurrentBlue Cross Blue Shield - MassachusettsPolicy 577

DXA body composition studies (dual-energy X-ray absorptiometry body composition)

This policy governs coverage and authorization requirements for DXA body composition studies for Blue Cross Blue Shield Massachusetts members across commercial and Medicare products; it states the payer's stance on investigational use and prior authorization rules for inpatient and outpatient settings.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyDXA body composition studies (dual-energy X-ray absorptiometry body composition)

Policy CodePolicy 577

Change TypeNo material change

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization when the procedure is performed inpatient.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Investigationalcoverage stance

Outpatient not coveredoutpatient status

Prior auth requiredinpatient auth

No specific CPTprocedure coding

2related policies

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Determinations

Not covered — investigational

Coverage stance

Investigational designation: Dual-energy X-ray absorptiometry (DXA) body composition studies are considered investigational.

Investigational designation applies across diagnoses and settings per document.

Coverage exceptions and authorization

Authorization and setting-specific coverage rules

Outpatient not covered: Outpatient DXA body composition studies are not a covered service for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO BlueSM, and Medicare PPO BlueSM.

Explicit outpatient noncoverage listed for those products.

Inpatient prior authorization: If the procedure is performed inpatient, precertification/preauthorization is required for all products.

Preauthorization requirement stated in policy.

Outpatient dual-energy X-ray absorptiometry (DXA) body composition studies are not a covered service for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO BlueSM, and Medicare PPO BlueSM members.

The referenced sections contain literature citations and practice guidance but do not provide additional, explicit coverage criteria, exclusions, or separate "not medically necessary" statements beyond the policy's overall investigational stance. These reference entries support the clinical discussion and background but do not establish coverage exceptions or specific authorization rules.

Dual-energy X-ray absorptiometry (DXA) body composition studies are designated investigational for all diagnoses. Systematic reviews and observational studies have evaluated DXA's agreement with reference methods and its use in research and monitoring, but the evidence does not demonstrate that DXA body composition testing, when used for clinical management, improves net health outcomes.

Indications (Informational)

Clinical indications described in background are informational only; despite potential uses, DXA body composition is considered investigational and not covered.

Informational clinical settings — not a coverage indication

Clinical scenarios discussed in background: Potential clinical settings include evaluation of undernourished patients and those with conditions affecting body composition (eg, anorexia nervosa, cachexia), monitoring after treatments such as bariatric surgery or antiretroviral therapy, assessment when BMI may be discordant with total fat mass (eg, body-building, edema), and assessment across growth and development (eg, infancy, childhood).

Although these clinical scenarios are described in the background literature, the policy designates DXA body composition studies as investigational and not covered.

Clinical research and assessment of body composition across various disease states — informational node

Research and referenced clinical applications (informational)

Research and disease-specific assessment: DXA is referenced in the literature for assessment of body composition across various clinical populations (eg, cystic fibrosis, cancer survivorship including lymphedema, sarcopenia, pediatric obesity, liver disease, and other conditions), and for research purposes to estimate regional and whole-body fat and lean mass.

Procedure and Diagnosis Codes

Prior Authorization

Coding and documentation guidance — providers should report services using up-to-date procedure, revenue, and diagnosis codes and include applicable modifiers.

Prior authorization: Providers must obtain prior authorization when required by member contract and payer policies before performing services. Documentation: Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes and include applicable modifiers. References: Follow ISCD (International Society for Clinical Densitometry) and ACR (American College of Radiology) practice guidelines where applicable. No explicit denial triggers are listed in this policy section; absence of a listed denial trigger does not guarantee coverage — providers must confirm member benefits and authorization requirements.

Prior Authorization required when specified by member contract and payer rules.
Report services with up-to-date CPT/HCPCS/Revenue/ICD-10 codes and applicable modifiers.
References: ISCD and ACR practice guidelines.

What Providers Need to Know

Prior Authorization

Inpatient precertification required

Precertification/preauthorization is required for all products if the procedure is performed in an inpatient setting.

Obtain prior authorization before performing inpatient DXA body composition studies

Note

References only — no additional prior authorization instructions

This section of the document provides references only and does not specify additional prior authorization requirements beyond those stated elsewhere in the policy.

No specific prior authorization procedures are described in the reference list

Step Therapy

Step therapy not specified

No step therapy requirements are specified in this portion of the policy.

Not Covered Services

DXA body composition studies performed in the outpatient setting are not covered for the listed Commercial and Medicare products; additionally, the policy designates DXA body composition use as investigational across diagnoses, which may result in denial of services billed for this purpose.

Key Terms

Definition — Dual-energy X-ray absorptiometry (DXA)

TermDual-energy X-ray absorptiometry (DXA)

DescriptionImaging that uses X-ray sources at two energy levels; differential attenuation estimates bone mineral content and soft tissue composition, allowing estimation of fat mass, lean body mass, and bone mass.

Assumptions/limitationsDXA-derived body composition assumes constant hydration of fat-free mass (73%), which can vary by disease state (67%–85%) and may affect accuracy.

Regional capabilityCan provide whole-body and regional (arms, legs, trunk) body composition measures, but soft tissue measures are only valid in areas without bone.

Related policiesUse for bone mineral density and vertebral fracture assessment addressed in separate policies #450 and #449.

Definition — Bioelectrical impedance analysis

Clinical and Technical Background

Body composition measurement methods quantify proportions of fat, lean mass, and bone and can be useful for evaluating undernourished patients or conditions that affect body composition (for example, anorexia nervosa, cachexia), for monitoring changes after interventions (such as bariatric surgery), or when BMI may not reflect true fat mass. Techniques include anthropometry, bioelectrical impedance, underwater weighing, and DXA, which estimates fat mass, lean mass, and bone mass and can provide regional measures but relies on assumptions (eg, constant hydration of fat-free mass) that may limit precision in some populations.